Fenoterol

Fenoterol
Clinical data
AHFS/Drugs.comMicromedex Detailed Consumer Information
Pregnancy
category
  • AU: A
Routes of
administration
Inhalation
ATC code
Legal status
Legal status
  • AU: S4 (Prescription only)
Pharmacokinetic data
Elimination half-life~6.5 hours
Identifiers
  • (RR,SS)-5-(1-hydroxy-2-{[2-(4-hydroxyphenyl)-1-methylethyl]amino}ethyl)benzene-1,3-diol
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.205.960
Chemical and physical data
FormulaC17H21NO4
Molar mass303.358 g·mol−1
3D model (JSmol)
  • Oc1cc(cc(O)c1)C(O)CNC(C)Cc2ccc(O)cc2
  • InChI=1S/C17H21NO4/c1-11(6-12-2-4-14(19)5-3-12)18-10-17(22)13-7-15(20)9-16(21)8-13/h2-5,7-9,11,17-22H,6,10H2,1H3 Y
  • Key:LSLYOANBFKQKPT-UHFFFAOYSA-N Y
  (verify)

Fenoterol is a β2-adrenergic receptor agonist and bronchodilator medication used in the treatment of asthma.

Fenoterol is produced and sold by Boehringer Ingelheim as Berotec N and in combination with ipratropium as Berodual N.

It was patented in 1962 and came into medical use in 1971, but in the 1980s concerns emerged about its safety and its use being associated with an increased risk of death.